Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 16, Issue 6, Pages 819-828Publisher
INFORMA HEALTHCARE
DOI: 10.1517/13543784.16.6.819
Keywords
beta-amyloid; active immunization; Alzheimer's disease; cognitive functions; immunotherapy; passive immunization; site-directed antibodies
Categories
Ask authors/readers for more resources
Recent clinical trials of active vaccination against beta-amyloid (A beta) have succeeded in clearing A beta plaques; however, further understanding of immunization with regards to inflammation and other hallmarks of Alzheimer's disease pathology is required. Antibodies generated with this first-generation vaccine may not have had the desired therapeutic properties or targeted the 'correct' mechanism, but they have opened the way for new clinical approaches, which are now under consideration. Passive administration of monoclonal antibodies directed to various regions of A beta peptide and/or administration of immunoconjugates of only small fragments of the N-terminal region may lead to the development of an improved second generation of A beta vaccines. Amyloid immunotherapy offers genuine opportunities for disease treatment; however, such an approach towards treating and preventing Alzheimer's disease patients requires careful antigen and antibody selection to maximize efficacy and minimize adverse events.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available